Page 66 - Read Online

tumor cell implantation and the origin of implanted cells: 4. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers?
traditional cell lines, primary cell culture, patient-derived Genetically distinct malignant conditions of the urothelium. Urol
tumor fragments, or tumor cells suspension. These Oncol Semin Orig Investig 2010;28:409-28.
factors influence tumor heterogeneity and the ability to 5. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz
model human tumor identity and behavior. [48] Moreover, P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y.
a greater understanding of UBC molecular biology has Epidemiology and risk factors of urothelial bladder cancer. Eur Urol
enabled the development of genetically engineered 2013;63:234-41.
mouse models that recapitulate genetic abnormalities 6. Druckrey H, Preussmann R, Ivankovic S, Schmidt CH, Mennel HD,
of human tumors and allow the study of individually Stahl KW. Selective induction of bladder cancer in rats by Dibutyl- and
altered genes in tumor behavior and response to therapy N-Butyl-N-butanol (4)-nitrosamine.Z Krebsforsch 1964;66:280-90.
in vivo. These models are created by knock out or knock 7. Soloway MS. Single and combination chemotherapy for primary
in of genes involved in transformation or malignancy murine bladder cancer. Cancer 1975;36:333-40.
such as HRAS, EGFR, TP53, PTEN, or RB as reviewed 8. Toyoshima K, Ito N, Hiasa Y, Kamamoto Y, Makiura S. Tissue
elsewhere. [49] These models provide a useful platform to culture of urinary bladder tumor induced in a rat by N-Butyl-N-(-4-
study genetic events associated with tumor development Hydroxybutyl) nitrosamine: establishment of cell line, nara bladder
and progression without losing tumor microenvironment tumor. J Natl Cancer Inst 1971;47:979-85.
and the immune system of the host. However, they can 9. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I,
fail to reproduce tumor heterogeneity and the genetic Moore RB. Characterization of a novel transplantable orthotopic rat
complexity of human tumors, which influence tumor bladder transitional cell tumour model. Br J Cancer 1999;81:638-46.
progression and metastasis. More recently, animal 10. Chan ES, Patel AR, Smith AK, Klein JB, Thomas AA, Heston WD,
models with functional immune systems are gaining Larchian WA. Optimizing orthotopic bladder tumor implantation in a
attention as a platform to test emerging immunotherapies syngeneic mouse model. J Urol 2009;182:2926-31.
such as anti-programmed death ligand-1. [50] 11. Palmeira C, Oliveira PA, Lameiras C, Amaro T, Silva VM, Lopes C,
Santos L. Biological similarities between murine chemical-induced
Despite the numerous existing UBC models, some and natural human bladder carcinogenesis. Oncol Lett 2010;1:373-7.
mechanisms underlying the pathophysiology of these 12. Oliveira PA, Colaço A, De La Cruz P LF, Lopes C. Experimental
tumors remains unknown, such as in the case of bladder carcinogenesis-rodent models. ExpOncol 2006;28:2-11.
Schistosome-related UBC. This is mainly due to the lack 13. Oliveira PA, Palmeira C, Colaço A, De La Cruz P LF, Lopes C. DNA
of a tractable animal model. Hsieh et al. have developed content analysis, expression of Ki-67 and p53 in rat urothelial lesions
a mouse model of S. haematobium urinary tract infection induced by N-butyl-N-(4-hydroxybutyl) nitrosamine and treated
after microinjection of purified S. haematobium eggs into with mitomycin C and Bacillus Calmette-Gue′rin. Anticancer Res
the urothelial bladder wall. [51] This model recapitulates 2006;26:2995-3004.
several aspects of human urothelial schistosomiasis 14. Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller
however, the development of infection-associated UBC K, Ørntoft TF. Gene expression in the urinary bladder: a common
was not reported and remains to be explored. carcinoma in situ gene expression signature exists disregarding
histopathological classification. Cancer Res 2004;64:4040-8.
Financial support and sponsorship 15. Williams PD, Lee JK, Theodorescu D. Molecular credentialing of
CB thanks the FCT (Fundação para a Ciência e a Tecnologia) rodent bladder carcinogenesis models. Neoplasia 2008;10:838-46.
for the PhD scholarship SFRH/ BD/80855/2011. 16. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, Bibby
M. Anticancer drug response and expression of molecular markers
Conflicts of interest in early-passage xenotransplanted colon carcinomas. Eur J Cancer
There are no conflicts of interest. 2004;40:298-307.
17. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model
REFERENCES for predicting chemotherapeutic drug response in cancer patients.
Clin Pharmacol Ther 2009;85:217-21.
1. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret 18. Dong X, Guan J, English JC, Flint J, Yee J, Evans K, Murray N,
T, Ribal MJ, Van der Heijden AG, Sherif A. European Association of Macaulay C, Ng RT, Gout PW, Lam WL, Laskin J, Ling V, Lam S,
Urology. EAU guidelines on muscle-invasive and metastatic bladder Wang Y. Patient-derived first generation xenografts of non-small
cancer: summary of the 2013 guidelines. Eur Urol 2014;65:778-92. cell lung cancers: promising tools for predicting drug responses for
2. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann personalized chemotherapy. Clin Cancer Res 2010;16:1442-51.
M, Hennenlotter J, Kruck S, Stenzl A. Economic aspects of bladder 19. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna
cancer: what are the benefits and costs? World J Urol 2009;27:295-300. I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell
3. Netto GJ. Molecular biomarkers in urothelial carcinoma of the J, Sidransky D. A pilot clinical study of treatment guided by
bladder: are we there yet? Nat Rev Urol 2012;9:41-51. Goebell PJ, personalized tumorgrafts in patients with advanced cancer. Mol
Knowles MA. Bladder cancer or bladder cancers? enetically distinct Cancer Ther 2011;10:1311-6.
malignant conditions of the urothelium. Urol Oncol Semin Orig 20. Bernardo C, Costa C, Amaro T, Gonçalves M, Lopes P, Freitas R,
Investig 2010;28:409-28. Gärtner F, Amado F, Ferreira JA, Santos L. Patient-derived Sialyl-

56
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ Issue 2 ¦ February 29, 2016 ¦